Condition: Anal Cancer · Sponsor: Assistance Publique - Hôpitaux de Paris
In January 2023, the first recommendations for anal cancer screening were issued by the French National Society of Coloproctology (SNFCP). These were the world's first national recommendations for anal cancer screening for at-risk patients, not limited to people living with HIV. They are based on screening for papillomavirus type 16 (HPV16) as the first line of defence, followed by reflex cytology in the event of a positive HPV16 smear and a proctological examination. In the event of abnormal cytology or proctological examination, high-resolution anoscopy (HRA) should be performed, but access to it is limited by the number of proctologists with the expertise to carry out this examination and the cost of the equipment. The development of biological markers could enable only patients at high risk of high-grade dysplasia/anal cancer to be referred for HRA. As part of the AIN3 cohort, we demonstrated that the markers ZNF582 and ASCL1, studied on anal smears taken when patients were included in the cohort, showed a significantly higher level of methylation in patients who subsequently progressed to anal cancer. The aim of this project is to test, in real-life conditions, the contribution of these methylation markers in the triage of asymptomatic patients eligible for anal cancer screening according to the SNFCP guidelines (MSM over 30 years of age living with HIV, women with a history of vulvar lesions or vulvar, women patients who have had a solid organ transplant for more than…
This description comes directly from the study's public registry record.
Valentine FERRE, PhD · 01.40.25.88.96 · valentinemarie.ferre@aphp.fr
Always discuss trial participation with your own doctor first.
| Cardiovascular Surgery and Transplantation Department Bichat-Claude Bernard Hospital | Paris, Île-de-France Region, France | Active Not Recruiting |
| Dermatology Department | Paris, Île-de-France Region, France | Not Yet Recruiting |
| Gynecology and Obstetrics Department Bichat-Claude Bernard Hospital | Paris, Île-de-France Region, France | Recruiting |
| Hepato-Gastroenterology, Digestive Oncology, and Proctology Department Bichat-Claude Bernard Hospital | Paris, Île-de-France Region, France | Active Not Recruiting |
| Infectious and Tropical Diseases Department Bichat-Claude Bernard Hospital | Paris, Île-de-France Region, France | Recruiting |
| Nephrology Department Bichat-Claude Bernard Hospital | Paris, Île-de-France Region, France | Active Not Recruiting |
| Pathological Anatomy and Cytology Department Bichat-Claude Hospital | Paris, Île-de-France Region, France | Active Not Recruiting |
| Pulmonology B and Lung Transplantation Department Bichat-Claude Bernard Hospital | Paris, Île-de-France Region, France | Active Not Recruiting |
| Virology Department Bichat-Claude Bernard Hospital | Paris, Île-de-France Region, France | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06792604